TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. trimmed its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 6.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,416 shares of the biopharmaceutical company’s stock after selling 1,627 shares during the period. Russell Investments Group Ltd.’s holdings in TG Therapeutics were worth $383,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Schonfeld Strategic Advisors LLC lifted its position in TG Therapeutics by 164.5% in the third quarter. Schonfeld Strategic Advisors LLC now owns 1,367,400 shares of the biopharmaceutical company’s stock worth $11,431,000 after purchasing an additional 850,507 shares during the period. 683 Capital Management LLC acquired a new stake in TG Therapeutics in the third quarter worth approximately $11,286,000. Charles Schwab Investment Management Inc. lifted its position in TG Therapeutics by 2.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,112,682 shares of the biopharmaceutical company’s stock worth $9,302,000 after purchasing an additional 31,872 shares during the period. Rafferty Asset Management LLC lifted its position in TG Therapeutics by 183.2% in the third quarter. Rafferty Asset Management LLC now owns 856,837 shares of the biopharmaceutical company’s stock worth $7,163,000 after purchasing an additional 554,309 shares during the period. Finally, Jump Financial LLC lifted its position in TG Therapeutics by 342.2% in the third quarter. Jump Financial LLC now owns 472,972 shares of the biopharmaceutical company’s stock worth $3,954,000 after purchasing an additional 366,012 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Price Performance

TGTX opened at $16.60 on Wednesday. The stock has a fifty day moving average of $15.31 and a 200-day moving average of $15.28. The firm has a market capitalization of $2.57 billion, a P/E ratio of 72.17 and a beta of 2.33. TG Therapeutics, Inc. has a 12-month low of $6.46 and a 12-month high of $30.07. The company has a quick ratio of 2.84, a current ratio of 3.62 and a debt-to-equity ratio of 0.63.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The business had revenue of $63.47 million during the quarter, compared to analysts’ expectations of $54.60 million. TG Therapeutics had a net margin of 14.24% and a return on equity of 31.34%. TG Therapeutics’s revenue for the quarter was up 713.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.28) EPS. Equities analysts forecast that TG Therapeutics, Inc. will post -0.01 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Laurence N. Charney sold 22,000 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total transaction of $351,340.00. Following the completion of the sale, the director now directly owns 215,229 shares in the company, valued at $3,437,207.13. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 9.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on TGTX shares. JPMorgan Chase & Co. restated an “overweight” rating and issued a $25.00 target price on shares of TG Therapeutics in a research report on Thursday, April 18th. LADENBURG THALM/SH SH upped their price target on TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. HC Wainwright upped their price target on TG Therapeutics from $45.00 to $49.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. StockNews.com cut TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 24th. Finally, B. Riley upped their price target on TG Therapeutics from $24.00 to $29.00 and gave the company a “buy” rating in a report on Monday, February 5th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.83.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.